S0003855|ENG|glial tumors, mixed|
S0004266|ENG|gliomas, mixed|
S0019946|ENG|GM-CSF - Fowlpox|
S0159837|ENG|I 131 lipiodol|
S0160632|ENG|Ibenzmethyzine Hydrochloride|
S0160634|ENG|Ibenzmethyzin Hydrochloride|
S0238076|ENG|iodine I 131 lipiodol|
S0242960|ENG|Irinotecan HCl|
S0365762|ENG|Lucorteum|
S0405123|ENG|management, dermatologic complications|
S0405168|ENG|management of mucositis|
S0405184|ENG|management of stomatitis|
S0405185|ENG|management of xerostomia|
S0424546|ENG|mechlorethamine/prednisone/procarbazine/vincristine|
S0458965|ENG|methotrexate methylaminopterin|
S0488501|ENG|mixed glial tumors|
S0497652|ENG|Monoclonal Anti-Alpha V Beta 3 Integrin|
S0497746|ENG|Monoclonal Antibody Anti-alpha V beta 3 Integrin|
S0497754|ENG|monoclonal antibody anti-CD20|
S0516132|ENG|mucositis management|
S0544763|ENG|N-acetyl dinaline|
S0614043|ENG|non-tumor cell derivative vaccine|
S0640966|ENG|O-(Chloroacetylcarbamoyl)fumagillol|
S0674877|ENG|oral complications of cancer and cancer therapy|
S0674879|ENG|oral complications of cancer therapy|
S0674882|ENG|oral complications of chemotherapy and head/neck radiation|
S0759772|ENG|pediatric brain tumor, germ cell|
S0759774|ENG|pediatric brain tumor, intracranial germ cell|
S0759871|ENG|pediatric CNS choriocarcinoma|
S0759873|ENG|pediatric CNS embryonal cell carcinoma|
S0759875|ENG|pediatric CNS endodermal sinus tumor|
S0759883|ENG|pediatric CNS teratoma|
S0759894|ENG|pediatric CNS tumor, germ cell|
S0759896|ENG|pediatric CNS tumor, intracranial germ cell|
S0759985|ENG|pediatric germ cell brain tumor|
S0759986|ENG|pediatric germ cell CNS tumor|
S0760104|ENG|pediatric intracrainal germ cell tumor|
S0760105|ENG|pediatric intracranial germ cell brain tumor|
S0760106|ENG|pediatric intracranial germ cell CNS tumor|
S0761785|ENG|PEG-L-Asparaginase(K-H)|
S0834297|ENG|plasma cell neoplasm, recurrent|
S0834298|ENG|plasma cell neoplasm, refractory|
S0855337|ENG|Polyethylene Glycollated Recombinant Human MGDF|
S0922065|ENG|protein tyrosine kinase inhibitor therapy|
S0979165|ENG|Rebeccamycin Analog|
S0986932|ENG|recurrent plasma cell neoplasm|
S0992759|ENG|refractory plasma cell neoplasm|
S1081030|ENG|Sandostatin-LAR|
S1130114|ENG|shionogi|
S1217722|ENG|stomatitis management|
S1304991|ENG|TCGF, Interleukin|
S1330421|ENG|Therapeutic Interleukin-11|
S1416684|ENG|tumor cell derivative vaccine|
S1418936|ENG|tumors, mixed glial|
S1459832|ENG|uterine corpus cancer cellular diagnosis|
S1462294|ENG|vaccine, non-tumor cell derivative|
S1462446|ENG|vaccine, tumor cell derivative|
S1499880|ENG|anti-CD20 monoclonal antibody|
S1531474|ENG|xerostomia management|
S1552905|ENG|(Z)-2-[4(1,2-diphenyl-1-butenyl)-phenoxyl]-N,N-dimethylethanamine|
S1600296|ENG|Asparaginase Erwinia|
S1639961|ENG|Bakers antifol|
S1651850|ENG|BCL2 Gene Anticode Oligodeoxynucleotide|
S1692410|ENG|Bisantrene HCL|
S1694390|ENG|Bis(Tetraazacyclotetradecane) Derivative|
S1699549|ENG|bleomycin/dacarbazine/doxorubicin/vinblastine|
S1699564|ENG|bleomycin/doxorubicin/etoposide/mechlorethamine/prednisone/vinblastine/vincristine|
S1719871|ENG|2'-Deoxy-2',2'-difluorocytidine|
S1784182|ENG|cancer therapy, oral complications of|
S1784183|ENG|cancer therapy, oral complications secondary to|
S1835927|ENG|cellular diagnosis, endometrial cancer|
S1862786|ENG|childhood CNS embryonal cell carcinoma|
S1862918|ENG|childhood germinoma brain tumor|
S1863030|ENG|childhood intracranial germinoma brain tumor|
S1863031|ENG|childhood intracranial mixed germ cell brain tumor|
S1863175|ENG|childhood mixed germ cell brain tumor|
S1867950|ENG|Chloramin|
S1884911|ENG|chromomycin A-3|
S1949876|ENG|complications management, dermatologic|
S1949932|ENG|complications of cancer therapy, oral|
S1950322|ENG|complications secondary to cancer therapy, oral|
S2002079|ENG|CT-2584HMS|
S2008805|ENG|CTX/DOX/PRED/VCR/VP-16|
S2020954|ENG|cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine|
S2020981|ENG|cyclophosphamide/doxorubicin/fluorouracil|
S2021132|ENG|cyclophosphamide/doxorubicin/prednisone/vincristine|
S2021265|ENG|cyclophosphamide/fluorouracil/methotrexate|
S2036236|ENG|4'-epi-Adriamycin|
S2040878|ENG|daunomycin|
S2040883|ENG|Daunomycin-HCL|
S2067704|ENG|DepoFoam encapsulated cytarabine|
S2067707|ENG|DepoFoam|
S2069921|ENG|dermatologic complications management|
S2103322|ENG|difluorodeoxycytidine|
S2133548|ENG|5-Aza-2'deoxycytidine/Decitabine|
S2140425|ENG|5-Chloro-2,4-dihydroxypyridinediol|
S2160079|ENG|drug toxicity|
S2191192|ENG|131-I-Anti-B1 Antibody|
S2191507|ENG|ellipticinium acetate|
S2257370|ENG|Estrone-Sulfate|
S2336852|ENG|Flavopirodol/HMR-1275|
S2344578|ENG|fluorouracil/irinotecan/leucovorin calcium|
S2344609|ENG|fluorouracil/leucovorin calcium/oxaliplatin|
S2348919|ENG|FOLFOX|
S2407823|ENG|kidney complications management|
S2408213|ENG|monoclonal antibody SGN-40|
S2408595|ENG|recombinant human lactoferrin|
S2408613|ENG|renal complications management|
S2408628|ENG|rhLF|
S2408953|ENG|anti-CD40 monoclonal antibody|
S2409030|ENG|anti-human CD40 monoclonal antibody|
S2409686|ENG|cervical intraepithelial neoplasia 1|
S2409687|ENG|cervical intraepithelial neoplasia 2|
S2409688|ENG|cervical intraepithelial neoplasia 3|
S2409797|ENG|CIN II|
S2459153|ENG|(Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine 2-Hydroxy-1,2,3-propanetricarboxylate (1:1)|
S2459154|ENG|(Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine|
S2459680|ENG|Biological_Process_Kind|
S2460551|ENG|Chemicals_and_Drugs_Kind|
S2460561|ENG|Chemotherapy_Regimen_Kind|
S2460888|ENG|Clinical_or_Research_Activity_Kind|
S2461716|ENG|Diagnostic_and_Prognostic_Factors_Kind|
S2462237|ENG|EO_Anatomy_Kind|
S2462245|ENG|EO_Findings_and_Disorders_Kind|
S2462315|ENG|Equipment_Kind|
S2462625|ENG|Findings_and_Disorders_Kind|
S2463076|ENG|Gene_Kind|
S2463093|ENG|Gene_Product_Kind|
S2463266|ENG|Abnormal_Cell_Kind|
S2464460|ENG|Lymphocyte-Depleted Classical Hodgkin's Lymphoma|
S2465002|ENG|Molecular_Abnormality_Kind|
S2465232|ENG|NCI_Kind|
S2465794|ENG|Organism_Kind|
S2466065|ENG|Pathway_Kind|
S2466592|ENG|Properties_or_Attributes_Kind|
S2467278|ENG|Anatomy_Kind|
S2468020|ENG|Therapeutic Lymphokine-Activated Killer Cell|
S2477884|ENG|gt|
S2477933|ENG|Hematopoietic Colony-stimulating Factors|
S2478868|ENG|Metastastatic Neoplasm to the Small Intestine|
S2482185|ENG|iodine I 131 chlorotoxin|
S2482314|ENG|pulmonary complications management|
S3762208|ENG|[qt_us]|
S3767395|ENG|Activity_Kind|
S3767638|ENG|Metastastatic Malignant Neoplasm to the Small Intestine|
S3913359|ENG|Principle Component Analysis|
S3913768|ENG|Topoisomerase II Inhibitor RTA 744|
S3920034|ENG|Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody|
S3920272|ENG|Product mislabeled|
S3920276|ENG|Program, failure to|
S3920687|ENG|2-(2-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylidene]-3-methoxy-2H-pyrrol-5-yl)-1H-indole|
S3920819|ENG|Cytoxan-Adriamycin-Fluorouracil Regimen|
S3920888|ENG|Device difficult to prepare|
S3920946|ENG|Difficult to program|
S3921173|ENG|False claim in device label|
S3921174|ENG|False claim|
S3921340|ENG|Improper device rinsing|
S3921363|ENG|Inadequate device cleaning|
S3921379|ENG|Incomplete instruction|
S3921479|ENG|Labeling or Instruction for use issue|
S3921480|ENG|Labeling, missing|
S3921736|ENG|Mislabeled|
S3921739|ENG|Missing device instruction|
S3921740|ENG|Missing device label|
S3922171|ENG|RC-1291 ghrelin mimetic|
S3922402|ENG|complications management, gastrointestinal|
S3922403|ENG|complications management, musculoskeletal|
S3922504|ENG|gastrointestinal complications management|
S3922634|ENG|management, gastrointestinal complications|
S3922635|ENG|management, musculoskeletal complications|
S3922672|ENG|musculoskeletal complications management|
S3922938|ENG|145858-52-2|
S3923166|ENG|TELINTRA|
S3923168|ENG|4-hydroxyacetanilide|
S3923684|ENG|Bleomycin-Etoposide-Adriamycin-Cytoxan-Oncovin-Procarbazine-Prednisone Regimen|
S3924002|ENG|FAC Regimen|
S4052797|ENG|12 [oz_ap]|
S4052799|ENG|12 [oz_tr]|
S4053027|ENG|[oz_t]|
S4053408|ENG|HYPO|
S4053420|ENG|Humanized Monoclonal Antibody MEDI-522|
S4053481|ENG|Kilogram Per Litre|
S4140220|ENG|Prednisolone P-21|
S4142307|ENG|Opioid Receptor Antagonist|
S4142689|ENG|CCG-59704 Regimen (Pediatric Study)|
S4143004|ENG|Nodular Sclerosis Hodgkin Lymphoma, , Syncytial Variant|
S4196026|ENG|tbl|
S4196592|ENG|Mith|
S4196615|ENG|R935788|
S4196641|ENG|Valeriana officinalis extrtact|
S4196696|ENG|cardiovascular complications management|
S4196857|ENG|9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)|
S4198309|ENG|Instruction missing|
S4202090|ENG|Prolonged Release Capsule Dosage Form|
S4202143|ENG|Slow Release Capsule Dosage Form|
S4202551|ENG|Cediranib|
S4202708|ENG|Gel-Forming Solution Dosage Form|
S4203003|ENG|Prolonged Release Tablet Dosage Form|
S4203011|ENG|R-935788|
S4203014|ENG|R788|
S4203070|ENG|Slow Release Tablet Dosage Form|
S4203404|ENG|Extended Action Tablet Dosage Form|
S4203644|ENG|Mitogen-Activated Protein Kinase Kianse Inhibitor|
S4244189|ENG|Philadelphia chromosome positive adult precursor lymphoblastic leukemia|
S4244196|ENG|R-(-)-gossypol|
S4244309|ENG|autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes|
S4244334|ENG|cediranib|
S4244383|ENG|complementary or alternative medical procedure|
S4244469|ENG|implanted fiducial-based imaging system|
S4244634|ENG|recurrent uterine corpus cancer|
S4244652|ENG|stage 0 uterine corpus cancer|
S4244676|ENG|stage II uterine corpus cancer|
S4244689|ENG|stage III uterine corpus cancer|
S4244699|ENG|stage IV uterine corpus cancer|
S4244718|ENG|stage, uterine corpus cancer|
S4244778|ENG|Anti-VEGFR-2 fully human monoclonal antibody IMC-1121B|
S4244905|ENG|stage I uterine corpus cancer|
S4609734|ENG|Progesterone-Receptor Antagonist ZK 230211|
S4611054|ENG|Asclepias Syriaca Fluid Extract|
S4623654|ENG|L-aspartic acid, N-(phosphonoacetyl), disodium salt|
S4623655|ENG|L-aspartic acid, N-(phosphonoacetyl), tetrasodium salt|
S4623680|ENG|MVA-BN prostate cancer vaccine|
S4623708|ENG|PDQ2008_06|
S4623724|ENG|Physician Data Query, 2008_06|
S4623755|ENG|TGF-B-resistant LMP-specific cytotoxic T-lymphocytes|
S4623768|ENG|URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vacine|
S4623777|ENG|WT-1 sensitized T cells|
S4623779|ENG|XmAb![TRADE MARK SIGN]!2513|
S4623780|ENG|XmAb™2513|
S4623823|ENG|anti-CD20 monoclonal antibody ALXN6000|
S4623827|ENG|anti-CD30 monoclonal antibody XmAb![TRADE MARK SIGN]!2513|
S4623828|ENG|anti-CD30 monoclonal antibody XmAb™2513|
S4623831|ENG|anti-CD38 fully human monoclonal antibody|
S4623833|ENG|anti-CD70 fully human monoclonal antibody MDX-1411|
S4623846|ENG|anti-endoglin human chimeric monoclonal antibody TRC105|
S4623853|ENG|autologous AD5F35-LMP-1/LMP-2-transduced dendritic cells|
S4623880|ENG|c-Met RTK inhibitor JNJ-38877605|
S4623882|ENG|c-Met receptor tyrosine kinase inhibitor JNJ-38877605|
S4623946|ENG|doxorubicin-LNRH agonist conjugate AEZS-108|
S4623971|ENG|flu matirx peptide|
S4623974|ENG|fluorine F 18 small peptide AH111585|
S4624011|ENG|indium In 111 monoclonal antibody HuPAM4|
S4624024|ENG|iodine 125-labeled anti-EGFr-425 monoclonal antibody|
S4624026|ENG|iodine 131-labeled 6-beta-iodomethyl-19-norcholesterol|
S4624028|ENG|iodine I 123 metaiodobenzylguanidine|
S4624040|ENG|live-attenuated Listeria monocytogenes vector encoding human mesothelin CRS-207|
S4624047|ENG|malignant glioma tumor lysate-pulsed dendritic cell vaccine|
S4624050|ENG|manganese superoxide dismutase-plasmid/liposome|
S4624056|ENG|mouse TYRP2 DNA vaccine|
S4624058|ENG|multipotent adult progenitor cells|
S4624059|ENG|multitargeted kinase inhibitor JNJ-26483327|
S4624060|ENG|multitargeted receptor tyrosine kinase inhibitor AP24534|
S4624066|ENG|non-tumor cell-derivative vaccine therapy|
S4624074|ENG|oral bisphosphonate MER-101|
S4624103|ENG|proteosome inhibitor CEP 18770|
S4624135|ENG|rhenium Re 186 Etidronate|
S4624152|ENG|sparfosate tetrasodium|
S4624165|ENG|systemic Hedgehog antagonist GDC-0449|
S4624198|ENG|tumor cell-derivative vaccine therapy|
S4624201|ENG|tyrosine kinase inhibitor MGCD265|
S4624206|ENG|vaccinia virus (wDD-CDSR)|
S4624215|ENG|yttrium Y 90 anti-CD66 monoclonal antibody BW250/183|
S4624217|ENG|zoledronic acid tablet|
S4624223|ENG|Ad5-Delta 24RGD|
S4624230|ENG|Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121|
S4624234|ENG|Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes|
S4624264|ENG|CD3/CD28 costimulated autologous T-cells|
S4624266|ENG|(5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride|
S4624314|ENG|Ga-68 labeled F(ab') 2- trastuzumab|
S4624325|ENG|HLA-A*2402-restricted multiepitope peptide vaccine|
S4624333|ENG|Hdm2 inhibitor JNJ-26854165|
S4624334|ENG|Hedgehog signaling pathway inhibitor BMS 833923|
S4624977|ENG|Paired Box Protein PAX-2|
S4625938|ENG|NaCH2O3|
S4628163|ENG|BUN/Creatinine Ratio|
S4723831|ENG|Filter - medical device|
S4805514|ENG|Operator Calibration Error|
S4806172|ENG|Care or Use of Device Issue|
S4806248|ENG|Cleaning, disinfecting or sterilization problem at user location|
S4806419|ENG|Failure of user to program|
S4807183|ENG|Oral Zoledronic Acid|
S4807196|ENG|PEG Laxative|
S4807270|ENG|Allogeneic Human Adult Bone Marrow-Derived Progenitor Cells|
S4807334|ENG|Polyethylene Glycol-Based Laxative|
S4807458|ENG|Renal Tumor RNA/CD40L-Transfected Dendritic Cell Vaccine|
S4808213|ENG|Bromoeosine|
S4808214|ENG|Bromofluoresceic Acid|
S4808236|ENG|C.I. 45380|
S4809278|ENG|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|
S4809479|ENG|Issues with Device Setup|
S4809611|ENG|Macrogol Laxative|
S4809696|ENG|Tyrosine Kinase Inhibitor MGCD265|
S4809700|ENG|null value|
S4810044|ENG|Tyrosine Kinase Inhibitor AP24534|
S4810045|ENG|Tyrosine Kinase Inhibitor BAY 73-4506|
S4810046|ENG|Tyrosine Kinase Inhibitor JNJ-26483327|
S4810306|ENG|Gastrointestinal Anastomotic Leakage|
S4810344|ENG|Hyperimmune Colostrum|
S4810514|ENG|NCI Developmental Therapeutics Program, 0812D|
S4810516|ENG|NCI Mouse Terminology, 0812D|
S4810517|ENG|NCI-GLOSS (Cancer.gov Dictionary), 0812D|
S4810518|ENG|NCI-GLOSS_0812D|
S4810519|ENG|NCI-HL7_0812D|
S4810520|ENG|NCI2008_12D|
S4810524|ENG|National Cancer Institute Thesaurus, 2008_12D|
S4810611|ENG|RENI_0812D|
S4810626|ENG|Registry Nomenclature Information System, 0812D|
S4810634|ENG|Ribonucleotide Reductase Messenger RNA Expression|
S4810693|ENG|Sustained Action Tablet Dosage Form|
S4810704|ENG|Applicatorfull|
S4810746|ENG|U.S. Centers for Disease Control and Prevention, 0812D|
S4810748|ENG|UCUM_0812D|
S4810750|ENG|Unified Code for Units of Measure, 0812D|
S4810835|ENG|Based on BioCarta online maps of molecular relationships, adapted for NCI use., 0812D|
S4810847|ENG|BioC_0812D|
S4810868|ENG|CDC_0812D|
S4810878|ENG|CDISC_0812D|
S4810890|ENG|COH_0812D|
S4810893|ENG|CRCH_0812D|
S4810912|ENG|CTCAE_0812D|
S4810929|ENG|Cancer Research Center of Hawaii, 0812D|
S4810936|ENG|Carbon C11Choline|
S4810945|ENG|City of Hope, 0812D|
S4810949|ENG|Clinical Data Interchange Standards Consortium, 0812D|
S4810956|ENG|Common Terminology Criteria for Adverse Events, 0812D|
S4810977|ENG|DCP_0812D|
S4810978|ENG|DICOM, 0812D|
S4810979|ENG|DICOM_0812D|
S4810989|ENG|DTP_0812D|
S4811005|ENG|Division of Cancer Prevention Program, 0812D|
S4811026|ENG|ERCC1 Messenger RNA Expression|
S4811052|ENG|Excision Repair Cross-Complementing 1 Messenger RNA Expression|
S4811060|ENG|FDA_0812D|
S4811076|ENG|Food and Drug Administration, 0812D|
S4811116|ENG|Health Level 7, 0812D|
S4811123|ENG|ICH_0812D|
S4811151|ENG|International Conference on Harmonization, 0812D|
S4811154|ENG|Iodine I 123 IMP-1072|
S4811155|ENG|Iodine I 123 IMP-1095|
S4811158|ENG|JAX_0812D|
S4811159|ENG|KEGG Pathway Database, 0812D|
S4811160|ENG|KEGG_0812D|
S4811181|ENG|Laser Doppler Velocimetry Phase Analysis Light Scattering System|
S4811182|ENG|Laser Doppler Velocimetry Phase Analysis Light Scattering|
S4811199|ENG|MYCN Messenger RNA Expression|
